Reuters
14 Sept 2026, 08:07 UTC · 2h ago
Verdict
Headline takes no side. We score BNTX +0.80 across one claim.
Our read: bullish.
BNTX score
+0.80
More positive than 88% of ticker scores this week
Price reaction
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen
What the story claims
1 claim · scored −1 bearish … +1 bullish
BioNTech's drug candidate gotistobart demonstrated a clinically meaningful overall survival benefit in a late-stage trial for a specific form of lung cancer.
More positive than 91% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Top 1 mover · tap to explore
More positive than 88% of ticker scores this week
Positive results from a late-stage trial showing survival benefit for a lung cancer drug candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
8h ago
Price reaction
Expected +0.80Actual —
BNTX hasn't traded since this ran. Last close $96.73 (Sep 11); the reaction starts at the next open.
BNTX chart →
